Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders
Insulin-Like Growth Factor 1 (IGF-1) is a neurotrophic polypeptide with crucial roles to play in Central Nervous System (CNS) growth, development and maturation. Following interrogation of the neurobiology underlying several neurodevelopmental disorders and Autism Spectrum Disorders (ASD), both reco...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-09-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00450/full |
| _version_ | 1819265367802904576 |
|---|---|
| author | Cyrus Vahdatpour Adam H Dyer Daniela Tropea |
| author_facet | Cyrus Vahdatpour Adam H Dyer Daniela Tropea |
| author_sort | Cyrus Vahdatpour |
| collection | DOAJ |
| description | Insulin-Like Growth Factor 1 (IGF-1) is a neurotrophic polypeptide with crucial roles to play in Central Nervous System (CNS) growth, development and maturation. Following interrogation of the neurobiology underlying several neurodevelopmental disorders and Autism Spectrum Disorders (ASD), both recombinant IGF-1 (mecasermin) and related derivatives, such as (1-3) IGF-1, have emerged as potential therapeutic approaches. Clinical pilot studies and early reports have supported the safety/preliminary efficacy of IGF-1 and related compounds in the treatment of Rett Syndrome, with evidence mounting for its use in Phelan McDermid Syndrome and Fragile X Syndrome. In broader ASD, clinical trials are ongoing. Here, we review the role of IGF-1 in the molecular etiologies of these conditions in addition to the accumulating evidence from early clinical studies highlighting the possibility of IGF-1 and related compounds as potential treatments for these childhood-onset neurodevelopmental disorders. |
| first_indexed | 2024-12-23T20:44:15Z |
| format | Article |
| id | doaj.art-235cfbfcbb3d4df08f4842c038e9d0d6 |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-23T20:44:15Z |
| publishDate | 2016-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-235cfbfcbb3d4df08f4842c038e9d0d62022-12-21T17:31:51ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2016-09-011010.3389/fnins.2016.00450218672Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental DisordersCyrus Vahdatpour0Adam H Dyer1Daniela Tropea2Trinity College DublinTrinity College DublinSchool of MedicineInsulin-Like Growth Factor 1 (IGF-1) is a neurotrophic polypeptide with crucial roles to play in Central Nervous System (CNS) growth, development and maturation. Following interrogation of the neurobiology underlying several neurodevelopmental disorders and Autism Spectrum Disorders (ASD), both recombinant IGF-1 (mecasermin) and related derivatives, such as (1-3) IGF-1, have emerged as potential therapeutic approaches. Clinical pilot studies and early reports have supported the safety/preliminary efficacy of IGF-1 and related compounds in the treatment of Rett Syndrome, with evidence mounting for its use in Phelan McDermid Syndrome and Fragile X Syndrome. In broader ASD, clinical trials are ongoing. Here, we review the role of IGF-1 in the molecular etiologies of these conditions in addition to the accumulating evidence from early clinical studies highlighting the possibility of IGF-1 and related compounds as potential treatments for these childhood-onset neurodevelopmental disorders.http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00450/fullFragile X SyndromeRett SyndromeAutism Spectrum DisordersIGF-1Phelan-McDermid Syndrome |
| spellingShingle | Cyrus Vahdatpour Adam H Dyer Daniela Tropea Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders Frontiers in Neuroscience Fragile X Syndrome Rett Syndrome Autism Spectrum Disorders IGF-1 Phelan-McDermid Syndrome |
| title | Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders |
| title_full | Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders |
| title_fullStr | Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders |
| title_full_unstemmed | Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders |
| title_short | Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders |
| title_sort | insulin like growth factor 1 and related compounds in the treatment of childhood onset neurodevelopmental disorders |
| topic | Fragile X Syndrome Rett Syndrome Autism Spectrum Disorders IGF-1 Phelan-McDermid Syndrome |
| url | http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00450/full |
| work_keys_str_mv | AT cyrusvahdatpour insulinlikegrowthfactor1andrelatedcompoundsinthetreatmentofchildhoodonsetneurodevelopmentaldisorders AT adamhdyer insulinlikegrowthfactor1andrelatedcompoundsinthetreatmentofchildhoodonsetneurodevelopmentaldisorders AT danielatropea insulinlikegrowthfactor1andrelatedcompoundsinthetreatmentofchildhoodonsetneurodevelopmentaldisorders |